19.09.2011
MagForce AG Completes Share Placement
Announcement in accordance with section 17 para. 2 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market on the Frankfurt Stock Exchange
Berlin, Sept 19, 2011 - MagForce AG (FSE:MF6), a leading medical technology company focusing on nanomedicine in oncology, has completed a share placement from its authorized capital. In connection with the transaction, the company’s nominal capital increased from EUR 4,070,681, divided into 4,070,681 no par value common shares in bearer form with an imputed nominal value of EUR 1.00 by EUR 56,360.00 to EUR 4,127,041.00. Dr. Peter Heinrich, CEO of MagForce AG, along with international investors participated in the share placement. The company excluded subscription rights to existing shareholders by its authority under sec. 6 para. 4 of its articles of incorporation (Satzung).
A total of 56,360.00 new common bearer shares with profit participation rights dating from January 1, 2011 were issued in the private placement at a price of EUR 12.42 per share. The gross proceeds of the capital increase in the amount of approx. EUR 700,000.00 will go to the company and will be used to finance its further growth.
ABOUT MAGFORCE:
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries.
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.